CERN Accélérateur de science

Accueil > CERN Experiments > MEDICIS Internal Notes

MEDICIS Internal Notes

Chercher dans 27 notices::
Conseils de recherche :: Recherche simple
Ajouté/modifié depuis: jusqu'à:
Trier par: Afficher: Format de sortie:
Derniers ajouts:
2020-09-14
19:12
Strengthening theranostics or radionuclide therapy in Pakistan / Khan, Irfan Ullah (INMOL Institute of Nuclear Medicine and Oncology)
In this project, we are interested to strengthen theranostics or radionuclide therapy in Pakistan. Due to its ability of targeting only cancerous cells, the field of theranostics is rapidly emerging worldwide and in developed countries, it is considered as real cancer diagnosis and treatment modality. [...]
MED-027.- Geneva : CERN, 2020 - 6. Fulltext: DOCX;

Notice détaillée - Notices similaires
2020-09-14
15:50
Facilities and Expertise in nuclear medicine / Khan, Irfan Ullah (INMOL Institute of Nuclear Medicine and Oncology)
This technical note is submitted following the accession of Pakistan to the MEDICIS collaboration as endorsed at the 5th Board, and required as follow-up..
MED-026.- Geneva : CERN, 2020 - 2. clinical qualification for radioisotopes: DOC;

Notice détaillée - Notices similaires
2020-02-17
09:50
Mass separation for the production of high specific activity Samarium-153 for targeted radionuclide therapy / Cocolios, Thomas Elias (KU Leuven (BE))
The radiolanthanide samarium-153 possesses highly favorable decay characteristics for nuclear medicine applications. 153Sm has a half-life of 1.93 d, decays into a stable daughter nuclide (153Eu) and emits β- particles (Emax = 705 keV, 635 keV) and γ photons (103 keV) suitable for therapy and SPECT imaging, respectively. [...]
MED-025.- Geneva : CERN, 2020 - 3. Sm-153 separation: PDF;

Notice détaillée - Notices similaires
2019-09-16
08:10
Mass separation of 225Ac from 227Ac and from irradiated Th targets to support Targeted Alpha Therapy / Cocolios, Thomas Elias (KU Leuven (BE))
Targeted Alpha Therapy (TAT) is a very promising approach for cancer treatment in nuclear medicine [1]. It suffers however greatly from the difficult access to suitable α-decaying isotopes so that only one radiopharmaceutical for α therapy has currently received FDA approval, namely 223RaCl2 under the brand Xofigo®. [...]
MED-024.- Geneva : CERN, 2019 - 3. Fulltext: DOC;

Notice détaillée - Notices similaires
2019-03-15
16:24
Imaging of iron metabolism
Iron is an essential and critical trace metal in the human body as it is involved in many vital processes like oxygen transport and redox reactions. However, excess iron is toxic and can cause oxidative stress (Dev, 2017). [...]
MED-023.- Geneva : CERN, 2019 - 2. Fulltext: PDF;

Notice détaillée - Notices similaires
2019-03-15
16:05
Non-invasive imaging of radioactive platinum chemotherapeutics for patient stratification
Platinum containing drugs are chemotherapeutics that are routinely used for cancer treatment in clinics worldwide. The main problems, however, are side effects and treatment resistance due to absent accumulation in tumors (Harper 2010). [...]
MED-022.- Geneva : CERN, 2019 - 2. Fulltext: PDF;

Notice détaillée - Notices similaires
2019-03-12
18:16
155/161Tb-labeled radioconjugates for cancer therapy with Auger electrons / Paulo, Antonio (C2TN-IST)
Auger-emitting radionuclides clinically used for SPECT imaging (e.g. 99mTc, 123I, 67Ga or 111In) started also to be envisaged for selective and targeted radiotherapy. [...]
MED-021.- Geneva : CERN, 2019 - 3. Fulltext: PDF;

Notice détaillée - Notices similaires
2019-03-12
11:47
Tb-IRMA-V: Terbium ISOL Radioisotopes for Medical Applications in Flanders / Cocolios, Thomas Elias (KU Leuven (BE))
Belgium has a strong tradition in molecular imaging, supported by a lively research community and a broad radioisotope industry (e.g. IBA for the production of cyclotrons, SCK•CEN for the production of 99Mo, IRE for the production of radioisotope generators, …) [...]
MED-020.- Geneva : CERN, 2019 - 3. Fulltext: PDF;

Notice détaillée - Notices similaires
2019-03-07
15:20
No-carrier-added 175Yb production at MEDICIS from external ILL target
Introduction & background: (state of the art and goal/motivation for the project) High-energy β- emitter 90Y(T1/2 :64 h ; Eβmean = 934 keV) and medium energy β- emitter 177Lu (T1/2: 6.73 d ; Eβ-mean = 154 keV) are the most widely used radionuclides for therapeutic radiopharmaceuticals. Monte Carlo simulations have shown that 177Lu might be more appropriate than 90Y for the treatment of minimal residual disease [1] and practical experience in clinics have proven the favorable properties of 177Lu regarding the significant reduction of undesired side effects to healthy organs (e.g [...]
MED-019.- Geneva : CERN, 2019 - 2. Fulltext: PDF;

Notice détaillée - Notices similaires
2019-03-07
15:16
No-carrier-added 169Er production at MEDICIS from target irradiated at ILL
Introduction & background: (state of the art and goal/motivation for the project) To date, 169Er (carrier-added) is used for the treatment of chronic rheumatoid arthritis in order to eliminate diseased synovium through irradiation and to improve joint function [1, 2]. However, its decay properties (T1/2 = 9.4 d, Eβmean = 219 keV) are very promising for radionuclide therapy of metastasized cancer diseases. [...]
MED-018.- Geneva : CERN, 2019 - 2. Fulltext: PDF;

Notice détaillée - Notices similaires